The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.51 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.52 — no flag raisedOK
- Earnings quality 90/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as REPLIGEN CORP reports it. History and quarterly detail are in the app.
- Product$738.0M
- Filtration Products$402.8M
- Chromatography Products$153.2M
- Proteins Products$97.4M
- Process Analytics Products$81.2M
Leadership changes
From REPLIGEN CORP's own filings, the day they're filed.
- Tony J. Hunt · departureeff. 2026-03-13
- Olivier Loeillot · Chief Commercial Officer · appointmenteff. 2024-09-01
- Karen A. Dawes · Director · appointmenteff. 2024-06-12
Latest filings
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about REPLIGEN CORP, every answer cited to the official filings🔒
- The Intelligence Brief — added when REPLIGEN CORP's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.